SS-31 (Elamipretide) Research Overview: Mitochondrial Mechanism & Preclinical Safety Literature

For laboratory and research use only. Not for human consumption.

SS-31, also known in the scientific literature as elamipretide, is a small synthetic peptide studied for its selective interaction with cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. This overview is scoped strictly to the published mechanism literature describing this cardiolipin interaction and to preclinical safety and toxicology data reported in animal and cell-based model systems. It does not describe or imply any human therapeutic application.

Key Facts

• SS-31 (elamipretide) is studied in the literature for its selective binding to cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane.
• Cardiolipin supports the structural organization of proteins in the mitochondrial electron transport chain, which is the basis of SS-31's proposed mechanism of interest.
• Mechanism studies on SS-31 have used isolated mitochondria preparations, cultured cell lines, and animal models.
• Preclinical toxicology literature on peptide compounds generally reports endpoints such as NOAEL, LD50, and MTD, along with organ histopathology data.
• This overview is informational and model-system-only; it does not describe or imply a human therapeutic indication.

What Is SS-31?

SS-31 belongs to a class of small synthetic peptides referred to in the pharmacology literature as Szeto-Schiller peptides, characterized by an alternating aromatic-cationic amino acid motif. This structural feature has been described in published research as enabling selective, reversible binding to cardiolipin rather than broad, non-specific membrane interaction. Because cardiolipin is concentrated almost exclusively in the inner mitochondrial membrane, this selectivity has made SS-31 a research tool for probing mitochondrial membrane biology in model systems.

The Cardiolipin-Binding Mechanism

Cardiolipin's Role in Mitochondrial Structure

Cardiolipin is a phospholipid with a distinctive four-acyl-chain structure that supports the organization and stability of protein complexes embedded in the inner mitochondrial membrane, including components of the electron transport chain. Published biochemical literature has described how alterations to cardiolipin composition or organization are associated with changes in mitochondrial membrane structure observed in various model systems.

Proposed Mechanism of SS-31 Interaction

Research on SS-31 has proposed that its cardiolipin-binding property allows it to associate with the inner mitochondrial membrane in a way that has been studied in relation to membrane curvature and the organization of respiratory chain protein complexes. Studies in isolated mitochondria and cultured cell systems have examined these membrane-level interactions as the basis for downstream biochemical measurements, such as oxygen consumption and reactive oxygen species output, reported in specific model systems.

Model Systems Used in Mechanism Research

Published mechanism studies on SS-31 span a range of preparations, from isolated mitochondria and permeabilized cell systems to whole-animal rodent models used to examine mitochondrial function markers under various experimental conditions. Each model system offers a different level of resolution: isolated mitochondria allow direct biochemical measurement, while animal models allow assessment of systemic and tissue-level endpoints.

Preclinical Safety and Toxicology Literature

Standard Toxicology Endpoints

Preclinical toxicology studies of peptide compounds generally report a standard set of endpoints, including the no observed adverse effect level (NOAEL), the median lethal dose (LD50) established in acute animal studies, and the maximum tolerated dose (MTD) identified across a dose-ranging study design. These endpoints are derived entirely from model-system data and are used by researchers to characterize a compound's safety margin within a study protocol, not to establish a human-use recommendation. A glossary of these and related toxicology terms is available in the preclinical safety and toxicology glossary covering NOAEL, LD50, and MTD.

Histopathological and Organ-System Assessment

Repeated-administration toxicology studies in animal models typically include histopathological examination of major organ systems following a defined study period, alongside standard clinical chemistry and hematology panels, to characterize any observed tissue-level changes associated with the compound under study.

SS-31 in the Context of Broader Mitochondrial Research

SS-31 is one of several compounds studied within the broader mitochondrial research literature, which includes work on compounds such as NAD-related research materials and MOTS-c. A comparison of how mitochondrial research topics are studied across these different compounds is available in MOTS-c vs. NAD in mitochondrial research, and a broader review of what the published literature describes for NAD-related cellular research is available in NAD cellular research: what the literature describes. Laboratories sourcing related research materials, such as NAD research compound, should apply the same independent verification standards described for other compounds in this space, confirmed through supplier testing and certificate of analysis documentation.

Frequently Asked Questions

What is SS-31 (elamipretide)?

SS-31, also referred to in the literature as elamipretide, is a small synthetic peptide studied for its interaction with cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Published research has focused on how this interaction relates to mitochondrial membrane structure and function in various model systems.

What is cardiolipin and why is it relevant to SS-31 research?

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane, where it supports the structural organization of proteins involved in the electron transport chain. Published studies describe SS-31 as binding selectively to cardiolipin, which researchers have used as a starting point for investigating downstream effects on mitochondrial membrane organization in model systems.

What preclinical safety endpoints have been studied for SS-31?

Preclinical toxicology literature on peptide compounds generally examines endpoints such as the no observed adverse effect level (NOAEL), median lethal dose (LD50) in animal models, and maximum tolerated dose (MTD), alongside histopathological assessment of organ systems following repeated administration in animal studies.

In what model systems has SS-31 mechanism research been conducted?

Published mechanism research on SS-31 has included isolated mitochondria preparations, cultured cell lines, and various animal models used to study mitochondrial membrane behavior and related biochemical endpoints under controlled experimental conditions.

Has SS-31 been approved for any human therapeutic use?

This overview does not address regulatory approval status and is scoped strictly to describing published mechanism and preclinical safety literature. SS-31 material discussed here is classified for laboratory and research use only, not for human consumption.

For laboratory and research use only. Not for human consumption.